ERCC1 measurements in clinical oncology

New England Journal of Medicine

Volumn 355, Issue 10, 2006, Pages 1054-1055

  Reed, Eddie ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; OXALIPLATIN;

BRAIN DEVELOPMENT; CANCER; CANCER SURVIVAL; CHEMOTHERAPY; CORRELATION ANALYSIS; DNA TRANSCRIPTION; EDITORIAL; EXCISION REPAIR; HUMAN; MEDICAL SOCIETY; MISMATCH REPAIR; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DNA REPAIR; DNA, NEOPLASM; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; LUNG NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33748418463     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe068162     Document Type: Editorial

References (12)

1. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
2. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91.
3. Reed E. Cisplatin, carboplatin, and oxaliplatin. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy: principles and practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2006:332-43.
4. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 2005;11:6100-2.
5. Reed E. Idem. Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology 1998;27:187-201.
6. Sancar A, Reardon JT. Nucleotide excision repair in E. coli and man. Adv Protein Chem 2004;69:43-71.
7. Mitchell JR, Hoeijmakers JH, Niedernhofer LJ. Divide and conquer: nucleotide excision repair battles cancer and ageing. Curr Opin Cell Biol 2003;15:232-40.
8. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998;273:23419-25.
9. Li Q, Ding L, Yu JJ, et al. Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells. Int J Oncol 1998;13:987-92.
10. Yan Q-W, Reed E, Zhong X-S, Thornton K, Guo Y, Yu JJ. MZF1 possesses a repressively regulatory function in ERCC1 expression. Biochem Pharmacol 2006;71:761-71.
11. Yu JJ, Thornton K, Guo Y, Kotz H Reed E. An ERCC1 splicing variant involving the 5′-UTR of the mRNA may have a transcriptional modulatory function. Oncogene 2001;20:7694-8.
12. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005;11:6212-7.